AMRN: Amarin fair value target cut at MKM after FDA decision
Inbox
| x |
Seeking Alfa
| x |
Triangles
|
|
3:17 PM (2 minutes ago)
| |||
Amarin fair value target cut at MKM after FDA decision • 3:16 PM
- The FDA awarded Amarin (AMRN +3.2%) three years of marketing exclusivity that extends through July 25, 2015, but not new chemical entity status, says analyst Jon LeCroy, lowering his fair value estimate to $1.75 from $2.50.
- He expects generic pharmaceutical companies to file Paragraph Four applications in the next several months, and for Amerin to file suit against the filers which will start a 30-month stay. "Vascepa has 40 issued and allowed U.S. patents that could protect Vascepa from generic entry to 2030, but the courts will decide whether any generic entrant would infringe on these patents."
- He expects Amarin to challenge the FDA's decision, but nothing to come of it, and thus lowers his valuation multiple on estimated 2017 sales to 3x from 4x.
AMRN price at time of publication: $1.92. Check AMRN price now »
Was this email forwarded to you? Learn more about Seeking Alpha Alerts here »
Focus Articles on AMRN
- FDA To Amarin: 'I Said Good Day, Sir!' by Quoth the Raven
- Amarin: Is No News Good News? by Quoth the Raven
- Amarin Delay Piques Investor Interest And Sparks Debate by VFC's Stock House
Press Releases on AMRN
- Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014 (GlobeNewswire)
- Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules(GlobeNewswire)
- Amarin to Present at the 2014 Leerink Global Healthcare Conference (GlobeNewswire)
Related Articles on AMRN
- Stock Watch Monday, 13 January 2014: Intercept Soars As Focus Shifts To Healthcare Market Trendsby VFC's Stock House
- While Amarin Continues To Go Rancid, Neptune Will Soar by Logical Assessment
- Stock Watch Friday, 10 January 2013: Mannkind Rallies, Sirius Should Satisfy by VFC's Stock House
Transcripts on AMRN
- Amarin's CEO Discusses Q3 2013 Results - Earnings Call Transcript by SA Transcripts
- Amarin's CEO Discusses Q2 2013 Results - Earnings Call Transcript by SA Transcripts
- Amarin Corporation plc Management Discusses Q2 2013 Results (Webcast) by SA Transcripts
No comments:
Post a Comment